Physician profile
John E Dudzinski
NPI 1386910933
$7,696.33
in general payments reported to CMS, 2019-2025
35 companies · $943 in 2025
The $943 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,098 · 2020: $270 · 2021: $593 · 2022: $2,675 · 2023: $758 · 2024: $1,360 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,060.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,943.65 | 2022-2025 | Navitor, Mitraclip, Xience Skypoint |
| Boston Scientific Corporation | $938.76 | 2019-2025 | Avvigo Guidance System, General - Therapies |
| Medtronic, INC. | $908.78 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Telescope |
| Abiomed | $565.05 | 2021-2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $510.72 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $455.04 | 2019-2025 | |
| Pfizer INC. | $320.30 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $297.41 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $260.23 | 2019-2024 | Farxiga, Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $258.04 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.84 | 2019-2022 | |
| Medtronic Vascular, INC. | $122.29 | 2019-2020 | |
| Shockwave Medical, INC | $105.88 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Kiniksa Pharmaceuticals, Ltd. | $91.51 | 2022-2023 | Arcalyst |
| Novo Nordisk INC | $91.18 | 2025 | Wegovy |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $86.60 | 2023-2024 | Uptravi, Opsumit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.32 | 2020-2022 | |
| Amarin Pharma, INC. | $78.22 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $66.39 | 2023 | |
| Edwards Lifesciences Corporation | $38.49 | 2019-2022 | |
| Biotronik INC. | $38.42 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $36.12 | 2024-2025 | Verquvo |
| Cardinal Health 200 LLC | $33.83 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $23.36 | 2024 | |
| Penumbra, INC. | $20.76 | 2023 | Indigo System |
| United Therapeutics Corporation | $19.86 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.50 | 2022 | |
| Apria Healthcare LLC | $18.14 | 2021 | |
| Allergan, INC. | $17.94 | 2019 | |
| Upsher-Smith Laboratories LLC | $16.39 | 2021 | |
| Terumo Medical Corporation | $15.56 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.95 | 2021 | |
| Dexcom, INC. | $14.18 | 2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $13.80 | 2022 | |
| Ge Healthcare | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dudzinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.